Soluble MHC I and soluble MIC molecules: potential therapeutic targets for cancer

Int Rev Immunol. 2011 Feb;30(1):35-43. doi: 10.3109/08830185.2010.543711.

Abstract

It has become clear that soluble MHC I (sMHC I) and soluble MIC (sMIC), which are highly elevated in sera of cancer patients, can be viewed to be tolerogenic, and that metalloproteinases are involved in their generation process. In this review, an overview is provided of the recent progress made in the sMHC I and sMIC fields, with emphasis on their structure, formation, and function, and the key-questions that still await answers are addressed. Understanding better their formation mechanism, it will become more feasible to modulate the immune responses in cancer patients by targeting molecules involved in their generation process.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Histocompatibility Antigens Class I / blood
  • Histocompatibility Antigens Class I / immunology*
  • Humans
  • Immunomodulation
  • Killer Cells, Natural / immunology
  • Killer Cells, Natural / metabolism
  • Metalloproteases / immunology
  • Metalloproteases / metabolism
  • Molecular Targeted Therapy
  • Neoplasms / blood
  • Neoplasms / immunology*
  • Solubility
  • T-Lymphocytes, Cytotoxic / immunology
  • T-Lymphocytes, Cytotoxic / metabolism

Substances

  • Histocompatibility Antigens Class I
  • MHC class I-related chain A
  • MICB antigen
  • Metalloproteases